We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
French biotechnology company Nosopharm has raised €2.4m in funding with Auriga Partners, Kreaxi and Alto Invest to accelerate the regulatory preclinical development of its first antibiotic molecule, NOSO-95179.